美股异动丨Biohaven盘前跌近14%，抑郁症药物未达中期试验主要目标

Core Viewpoint - Biohaven's experimental depression drug failed to meet primary goals in mid-stage trials, leading to a nearly 14% pre-market drop in stock price to $9.31 [1] Group 1: Clinical Trial Results - The drug BHV-7000 did not show significant improvement in depressive symptoms compared to a placebo in a six-week trial involving patients with severe depression [1] - The company considers the subgroup analysis for depression as "hypothetical exploration" and does not plan to conduct further psychiatric clinical trials [1] Group 2: Strategic Focus - Biohaven intends to concentrate resources on key priority areas such as immunology, obesity, and epilepsy, aiming for a shift in focus by 2026 [1]